<!DOCTYPE html SYSTEM "about:legacy-compat">
<html class="no-js">
  <head>
    <meta charset="utf-8"/>
    <meta http-equiv="X-UA-Compatible" content="IE=edge,chrome=1"/>
    <title>D.C. Law Library - D.C. Act 23-387. Access to Biosimilars Amendment Act of 2020.</title>
    <meta property="st:title" content="D.C. Act 23-387. Access to Biosimilars Amendment Act of 2020."/>
    <meta name="description" content="Browse the laws and code of the District of Columbia"/>
    <meta name="viewport" content="width=device-width"/>
    <link href="https://fonts.googleapis.com/css?family=Open+Sans:400italic,700italic,400,700" rel="stylesheet" type="text/css"/>
    <link rel="stylesheet" type="text/css" href="/css/main.css" media="screen"/>
    <link rel="stylesheet" type="text/css" href="/css/print.css" media="print"/>
    <script type="text/javascript">
        var _paq = _paq || [];
        _paq.push(['trackPageView']);
        _paq.push(['enableLinkTracking']);
        (function() {
            var u="//analytics.code.dccouncil.us/";
            _paq.push(['setTrackerUrl', u+'piwik.php']);
            _paq.push(['setSiteId', 1]);
            var d=document, g=d.createElement('script'), s=d.getElementsByTagName('script')[0];
            g.type='text/javascript'; g.async=true; g.defer=true; g.src=u+'piwik.js'; s.parentNode.insertBefore(g,s);
        })();
        
        window.searchHost = 'https://search.code.dccouncil.us';
        window.queryUrl = '/v1/search';
    </script>
    <noscript>
      <p>
        <img src="//analytics.code.dccouncil.us/piwik.php?idsite=1" style="border:0;" alt=""/>
      </p>
    </noscript>
  </head>
  <body>
    <header>
      <section class="container">
        <a href="http://dccouncil.us">
          <img src="/css/header_logo.png" alt="DC Seal" class="header_logo"/>
        </a>
        <h1 id="sitename">
          <a href="/dc/council/acts/23-387.html">D.C. Act 23-387. Access to Biosimilars Amendment Act of 2020.</a>
        </h1>
        <div class="right no-print search" id="search"> </div>
      </section>
    </header>
    <main class="main container">
      <div class="clearfix" style="width: 100%;">
        <aside id="sidebar" class="col3 quiet">
          <h2>You Are Here</h2>
          <ul class="ancestors">
            <li data-search-path="library|D.C. Code" data-search-heading="D.C. Code" data-search-default="true"/>
            <li data-search-path="library" data-search-heading="All Documents">↪ <a href="/">D.C. Law Library</a></li>
            <li data-search-path="library|dclaws" data-search-heading="D.C. Laws">↪ <a href="/dclaws/">D.C. Laws Codified in the D.C. Code</a></li>
            <li data-search-path="library|dclaws|23" data-search-heading="">↪ <a href="/dclaws/23/">Council Period 23</a></li>
            <li data-search-path="library|dclaws|23|permanent" data-search-heading="">↪ <a href="/dclaws/23/permanent/">Permanent Laws</a></li>
            <li data-search-path="library|dclaws|23|permanent|pending" data-search-heading="">↪ <a href="/dclaws/23/permanent/pending/">Acts pending congressional review</a></li>
            <li data-search-path="library|dclaws|23|permanent|pending|D.C. Act 23-387" data-search-heading="D.C. Act 23-387">↪ D.C. Act 23-387. Access to Biosimilars Amendment Act of 2020.</li>
          </ul>
          <div class="document-info">
            <h2>Law Information</h2>
            <dl>
              <dt>Cites</dt>
              <dd>D.C. Act 23-387 (<a class="internal-link" href="https://lims.dccouncil.us/downloads/LIMS/43164/Signed_Act/B23-0430-Signed_Act.pdf">PDF</a>)<br/>67 DCR 9880<br/></dd>
              <dt>Effective</dt>
              <dd>Nov. 16, 2020 (Projected)</dd>
              <dt>Legislative History (<a href="https://lims.dccouncil.us/Legislation/B23-0430">LIMS</a>)</dt>
            </dl>
          </div>
          <section class="cta">
            <p>
              <a href="mailto:code@dccouncil.us?subject=[ERROR]+/dc/council/acts/23-387.html">Report Error</a>
            </p>
            <p>
              <a href="mailto:code@dccouncil.us?subject=[FEEDBACK]+/dc/council/acts/23-387.html">Website Feedback</a>
            </p>
            <p>We cannot respond to questions regarding the law.</p>
          </section>
        </aside>
        <section class="col8 body">
          <section class="pending_notice">
        This act is <strong>not yet codified</strong> in the D.C. Code because it is not yet effective as law. It is projected to become effective on Nov. 16, 2020.
      </section>
          <h1 id="/dc/council/acts/23-387.html">D.C. Act 23-387. Access to Biosimilars Amendment Act of 2020.</h1>
          <section class="content">
            <p style="text-align: center;">AN ACT</p>
            <p style="font-style: italic">To amend the District of Columbia Prescription Drug Price Information Act to authorize licensed pharmacists to dispense interchangeable biological products, and to require notifications to physicians, with certain exceptions, when interchangeable biological products are dispensed.</p>
            <p>BE IT ENACTED BY THE COUNCIL OF THE DISTRICT OF COLUMBIA, That this act may be cited as the "Access to Biosimilars Amendment Act of 2020".</p>
            <p id="&#xA7;2"><span class="level-num">Sec. 2. </span>The District of Columbia Prescription Drug Price Information Act, effective September 10, 1976 (D.C. Law 1-81; D.C. Official Code § 48-801.01 <em>et seq.</em>), is amended as follows:</p>
            <p class="marginalia">Amend <a href="/dc/council/code/sections/48-804.51.html">§ 48-804.51</a></p>
            <p class="text-indent-1"><span class="level-num" id="&#xA7;2(a)">(a)</span> Section 2 (D.C. Official Code § 48-804.51) is amended by adding new paragraphs (1A) and (2A) to read as follows:</p>
            <p class="text-indent-2">"<span class="level-num" id="">(1A)</span> "Biological product" shall have the same meaning as provided in 42 U.S.C. § 262.</p>
            <p class="text-indent-2">"<span class="level-num" id="">(2A)</span> "Interchangeable biological product" means a biological product that is:</p>
            <p class="text-indent-3">"<span class="level-num" id="">(A)</span> Licensed and determined by the United States Food and Drug Administration to meet the standards for interchangeability under 42 U.S.C. § 262(k)(4); or</p>
            <p class="text-indent-3">"<span class="level-num" id="">(B)</span> Determined to be biosimilar to and interchangeable with a reference biological product as stated in the latest edition of, or supplement to, the United States and Food and Drug administration's ("FDA") publication, "Lists of Licensed Biological Products with Reference Product Exclusivity and Biosimilarity or Interchangeability Evaluations" (known as the Purple Book).".</p>
            <p class="marginalia">Amend <a href="/dc/council/code/sections/48-803.01.html">§ 48-803.01</a></p>
            <p class="text-indent-1"><span class="level-num" id="&#xA7;2(b)">(b)</span> Section 301 (D.C. Official Code § 48-803.01) is amended by adding a new subsection (d) to read as follows:</p>
            <p class="text-indent-1">"<span class="level-num" id="">(d)</span> The Board of Pharmacy and the Board of Medicine shall maintain a link on their websites to the current list of biological products determined by the FDA to be interchangeable with a specific biological product.".</p>
            <p class="marginalia">Amend <a href="/dc/council/code/sections/48-803.02.html">§ 48-803.02</a></p>
            <p class="text-indent-1"><span class="level-num" id="&#xA7;2(c)">(c)</span> Section 302 (D.C. Official Code § 48-803.02) is amended as follows:</p>
            <p class="text-indent-2"><span class="level-num" id="&#xA7;2(c)(1)">(1)</span> The section heading is amended to read as follows:</p>
            <p id="">"<span class="level-num">Sec. 302. </span>Dispensing of generically equivalent drug product or interchangeable biological product.</p>
            <p class="text-indent-2"><span class="level-num" id="&#xA7;2(c)(2)">(2)</span> Subsection (a) is amended by striking the phrase "generically equivalent drug product" wherever it appears and inserting the phrase "generically equivalent drug product or interchangeable biological product" in its place.</p>
            <p class="text-indent-2"><span class="level-num" id="&#xA7;2(c)(3)">(3)</span> Subsection (b) is amended by striking the phrase "drug by generic name" and inserting the phrase "drug by generic name or interchangeable biological product" in its place.</p>
            <p class="marginalia">Amend <a href="/dc/council/code/sections/48-803.03.html">§ 48-803.03</a></p>
            <p class="text-indent-1"><span class="level-num" id="&#xA7;2(d)">(d)</span> Section 303(2) (D.C. Official Code § 48-803.03(2)) is amended by striking the phrase "generically equivalent drug product" and inserting the phrase "generically equivalent drug product or interchangeable biological product" in its place.</p>
            <p class="marginalia">Amend <a href="/dc/council/code/sections/48-803.03a.html">§ 48-803.03a</a></p>
            <p class="text-indent-1"><span class="level-num" id="&#xA7;2(e)">(e)</span> Section 303a(a) (D.C. Official Code § 48-803.03a(a)) is amended by striking the phrase "drug substitution" and inserting the phrase "drug substitution, including an interchangeable biological product," in its place.</p>
            <p class="marginalia">Amend <a href="/dc/council/code/sections/48-803.04.html">§ 48-803.04</a></p>
            <p class="text-indent-1"><span class="level-num" id="&#xA7;2(f)">(f)</span> Section 304 (D.C. Official Code § 48-803.04) is amended by striking the phrase "substituted under this title," and inserting the phrase "substituted under this title, including the substitution of an interchangeable biological product," in its place.</p>
            <p class="marginalia">Amend <a href="/dc/council/code/sections/48-803.05.html">§ 48-803.05</a></p>
            <p class="text-indent-1"><span class="level-num" id="&#xA7;2(g)">(g)</span> Section 305 (D.C. Official Code § 48-803.05) is amended as follows:</p>
            <p class="text-indent-2"><span class="level-num" id="&#xA7;2(g)(1)">(1)</span> Subsection (a) is amended by striking the phrase "under this title" and inserting the phrase "under this title, including the substitution of an interchangeable biological product" in its place.</p>
            <p class="text-indent-2"><span class="level-num" id="&#xA7;2(g)(2)">(2)</span> Subsection (b) is amended by striking the phrase "generically equivalent drug products drugs" and inserting the phrase "generically equivalent drugs products or an interchangeable biological product" in its place.</p>
            <p class="marginalia">New § 48-803.06</p>
            <p class="text-indent-1"><span class="level-num" id="&#xA7;2(h)">(h)</span> A new section 306 is added to read as follows:</p>
            <p id="">"<span class="level-num">Sec. 306. </span>Pharmacist notification to prescriber of substitution of interchangeable biological product.</p>
            <p class="text-indent-1">"<span class="level-num" id="">(a)</span> Within 5 business days after dispensing a biological product to a patient, the dispensing pharmacist or the pharmacist's designee shall communicate to the prescriber the specific biological product dispensed, including the name and manufacturer of the biological product; except, that this communication shall not be required if the FDA has not approved an interchangeable biological product for the biological product prescribed to the patient or a refill prescription is not changed from the biological product dispensed on the most recent filling of the prescription.</p>
            <p class="text-indent-1">"<span class="level-num" id="">(b)</span><span class="level-num" id="">(1)</span> Except as provided under subsection (c) of this section, the communication required under subsection (a) of this section shall be provided by making an entry that is electronically accessible to the health care provider through:</p>
            <p class="text-indent-3">"<span class="level-num" id="">(A)</span> An interoperable electronic medical records system;</p>
            <p class="text-indent-3">"<span class="level-num" id="">(B)</span> An electronic prescribing technology; or</p>
            <p class="text-indent-3">"<span class="level-num" id="">(C)</span> A pharmacy benefits management system.</p>
            <p class="text-indent-2">"<span class="level-num" id="">(2)</span> Making an entry through a mechanism listed in paragraph (1) of this subsection shall be presumed to provide the communication to the prescriber required under subsection (a) of this section.</p>
            <p class="text-indent-1">"<span class="level-num" id="">(c)</span> If the mechanisms listed in subsection (b)(1) of this section are unavailable, the communication required under subsection (a) of this section may be provided by facsimile, telephone, electronic transmission, or other means.</p>
            <p class="text-indent-1">"<span class="level-num" id="">(d)</span> The requirements under subsections (a) through (c) of this section shall not apply to dispensing pharmacists or their designees at a health maintenance organization that operates as a group model for services furnished through internal pharmacy operations for members and patients of the health maintenance organization.".</p>
            <p id="&#xA7;3"><span class="level-num">Sec. 3. </span>Fiscal impact statement.</p>
            <p>The Council adopts the fiscal impact statement in the committee report as the fiscal impact statement required by section 4a of the General Legislative Procedures Act of 1975, approved October 16, 2006 (120 Stat. 2038; D.C. Official Code § 1-301.47a).</p>
            <p id="&#xA7;4"><span class="level-num">Sec. 4. </span>Effective date.</p>
            <p>This act shall take effect following approval by the Mayor (or in the event of veto by the</p>
            <p>Mayor, action by the Council to override the veto), a 30-day period of congressional review as provided in section 602(c)(l) of the District of Columbia Home Rule Act, approved December 24, 1973 (87 Stat. 813; D.C. Official Code § 1-206.02(c)(l)), and publication in the District of Columbia Register.</p>
          </section>
        </section>
      </div>
    </main>
    <footer>
      <section class="container center">
        <p>The codes and laws on this website are in the public domain.</p>
        <p>
              Please do not scrape. Instead, bulk download the <a href="https://github.com/dccouncil/dc-law-html">HTML</a> or <a href="https://github.com/dccouncil/dc-law-xml">XML</a>.
            </p>
        <p>Powered by the non-profit <a href="http://www.openlawlib.org/">Open Law Library</a>.</p>
      </section>
    </footer>
    <script type="text/javascript" src="/js/main.js"> </script>
  </body>
</html>
